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Risk factors for EM relapse following allogeneic HCT for acute leukemia
Characteristics
Percent of pts
w/ AML EM
relapse (n5 26)
Percent of all other
AML pts (n5 231)
Hazard Ratio
(p-value)
Percent of patients
with ALL EM
relapse (n5 23)
Percent of all
other ALL patients
(n5 85)
Hazard Ratio
(p-value)
FAB M4/M5 50% (n5 13) 30% (n5 70) 2.5 (0.02)
Age\18 years at diagnosis 35% (n5 9) 13% (n5 31) 3.1 (0.006) 43% (n5 10) 38% (n5 32) 1.1 (0.71)
EM disease prior to HCT 35% (n5 9) 10% (n5 22) 4.6 (\0.001) 57% (n5 13) 35% (n5 30) 1.7 (0.23)
High risk cytogenetics1 54% (n5 14) 27% (n5 62) 2.9 (0.006) 26% (n5 6) 39% (n5 33) 0.6 (0.26)
Advanced disease at HCT2 62% (n5 16) 36% (n5 83) 2.6 (0.02) 43% (n5 10) 24% (n5 20) 2.7 (0.02)
TBI in conditioning 12% (n5 3) 10% (n5 23) 1.3 (0.70) 47% (n5 11) 71% (n5 65) 0.4 (0.02)
Myeloablatvie conditioning 96% (n5 25) 80% (n5 184) 5.8 (0.08) 91% (n5 21) 95% (n5 81) 0.4 (0.22)
HLA matched donor 96% (n5 25) 83% (n5 192) 2.7 (0.10) 91% (n5 21) 84% (n5 71) 4.8 (0.13)
1High risk cytogenetics defined as complex karyotype, 5q-, monosomy7/7q-, and/or FLT-3 positive for AML and MLL gene rearrangement and/or Phil-
adelphia chromosome in ALL.
2Advanced disease defined as CR31 or refractory disease at time of transplant.
S178 Oral Presentationsunderwent allogeneic HCT for acute leukemia at the University of
Michigan between January 2001 and May 2008 to characterize EM
relapse, identify predictive variables and assess outcomes.
Following HCT for AML in 257 pts, the 5-yr cumulative inci-
dences of isolated EM and marrow relapse were 9% (n5 24) and
29% (n5 73), respectively. Combined relapse occurred in \1%
of pts (n5 2). EM relapse occurred later than marrow relapse
(median 348d vs. 112d, p\0.001). Skin and soft tissue were
most frequently involved (69%, n5 18). Factors predictive of
EM relapse included advanced disease (CR3+/refractory) at HCT
(HR5 2.6, p5 0.02), high risk cytogenetics (HR5 2.9,
p5 0.006), and AML FAB class M4 or M5 (HR5 2.5, p5 0.02).
These factors also predicted future marrow relapse. A history of
EM disease prior to HCT was predictive of future EM relapse
(HR5 4.6, p\0.001), but not marrow relapse (HR5 1.2,
p5 0.63). Interestingly, pts aged #18 at diagnosis were more likely
to develop EM relapse than adults (HR5 3.1, p50.006). Treat-
ment for EM relapse included systemic chemotherapy (n5 19), ra-
diation to chloromas (n5 12), and/or DLI (n5 8). Overall survival
after EM relapse was 30% at 1-yr and 11% at 2-yrs.
In 108 pts receiving HCT for ALL, the 5-yr cumulative incidence
of isolated EM relapse was 15% (n5 16), isolated marrow relapse
was 19% (n5 19) and combined relapse was 6% (n5 7). Isolated/
combined EM relapses occurred later than isolated marrow relapse
(median 260d vs. 96d, p5 0.05). EM relapse most often occurred
in the classic ALL sanctuary sites, CNS and testes (61%, n5 14),
but chloromas also occurred. Seven of 12 pts with CNS relapse
had received craniospinal radiation pre-HCT. Factors related to
EM relapse included advanced disease at HCT (HR5 2.7,
p5 0.02) and TBI-based conditioning (HR 0.4, p5 0.02), a pattern
echoed in marrow relapse. Unlike in AML, EM disease prior to
HCT did not predict EM relapse (HR5 1.7, p5 0.23). Treatments
for EM relapse included systemic chemotherapy (n5 15), radiation
to EM sites (n5 8), and/or DLI (n5 1). Overall survival after EM
relapse was 34% at 1-yr and 20% at 2-yrs.
Isolated EM relapse after allogeneic HCT for acute leukemia is
a surprisingly significant contributor to relapse. As with marrow re-
lapses, current treatment strategies salvage only a small proportion
of pts.62
PROGNOSIS OF ADULT PATIENTS WITH NON-M3 AML AFTER FIRST RE-
LAPSE
Kurosawa, S.1, Yamaguchi, T.2, Uchida, N.3, Sakura, T.4,
Kanamori, H.5, Usuki, K.6, Yamashita, T.7, Watanabe, M.8,
Yakushiji, K.9, Yano, S.10, Nawa, Y.11, Taguchi, J.12, Takeuchi, J.13,
Takaue, Y.1, Fukuda, T.1 1National Cancer Center Hospital, Tokyo, Ja-
pan; 2University of Tokyo, Japan; 3Toranomon Hospital, Japan; 4Saisei-
kai Maebashi Hospital; 5Kanagawa Cancer Center, Japan; 6NTT Kanto
Medical Center, Japan; 7Tokyo Metropolitan Komagome Hospital, Japan;
8Fujita Health University, Japan; 9Kurume University, Japan; 10Jikei
University, Japan; 11Ehime Prefectural Central Hospital, Matsuyama,
Japan; 12Nagasaki University, Japan; 13Nihon University, JapanBackground:The prognosis of patients who suffered first relapse re-
mains challenging, with little available prognostic factors. To clarify
factors predicting outcome of these patients, we performed a nation-
wide retrospective survey of 1,015 relapsed patients.
Methods:We collected clinical data of 2,029 patients from 70 cen-
ters, who were diagnosed with AML other than M3 between 1999
and 2006, aged 16 to 70 years, andwho had achieved complete remis-
sion (CR1) after 1 or 2 courses of induction chemotherapy.
Results: Of the 1,535 patients who did not receive allo-HCT in
CR1, 1,015 relapsed and were eligible for this analysis. The median
age was 53 years, and the median follow-up of the surviving pa-
tients was 1,457 days. The proportions of patients with favorable,
intermediate, unfavorable and unknown cytogenetic risks by
SWOG criteria were, respectively, 21%, 52%, 17% and 10%.
The median interval from CR1 to relapse was 264 days. The
3-year overall survival (OS) after relapse was 30%. Of the 931 pa-
tients whose detailed clinical data following first relapse were avail-
able, 464 achieved CR2 (50%). The 3-year OS after relapse of the
patients who achieved CR2 and those who did not were 48% and
11%, respectively (p\0.001). Among the 931 patients who experi-
enced first relapse, 494 received salvage allo-HCT. Donor sources
for salvage HCT were HLA-matched related (29%), mismatched
related (10%), unrelated BM (37%), or unrelated CB (23%). The
conditioning regimens were myeloablative (65%, median age: 37
years) or reduced-intensity (35%, median age: 55 years) regimens.
The 3-year OS of 494 patients who received salvage allo-HCT was
44%, whereas that of the remaining 437 patients who did not was
12% (p\0.001). The OS of the 306 patients who received salvage
HCT in CR2 was comparable to that of patients who received allo-
HCT in CR1 (3-year OS after CR1, 67% vs. 67%). Multivariate
analyses showed that an interval from CR1 to relapse (.1 year),
performance of salvage allo-HCT, a single course of induction
therapy to achieve CR1, and favorable cytogenetic risk were signif-
icantly associated with better survival after relapse. In addition, lack
of dysplasia and lower WBC count (\20,000/ml) at diagnosis be-
sides the above prognostic factors for OS were significantly associ-
ated with achievement of CR2.
Conclusion: Our data suggest that patients who achieve CR2 after
relapse would have moderate prognosis especially when a salvage
allo-HCT is performed during CR2.63
PRE-TRANSPLANT CONSOLIDATION CHEMOTHERAPY DOES NOT IM-
PROVE RATES OF RELAPSE FOLLOWING REDUCED INTENSITY CONDI-
TIONING (RIC) HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)
FOR AML IN CR1
McCormack, S.E.1, Cao, Q.2, Warlick, E.D.1 1University of Minnesota,
Minneapolis, MN; 2University of Minnesota, Minneapolis, MN
Background: RIC HCT is an evolving post-remission treatment
modality for AML. While previous reports demonstrate no benefit
to consolidation chemotherapy prior tomyeloablative HCT, the im-
pact on outcomes post RIC HCT is unknown.
Methods and Patients: We retrospectively reviewed all adult pa-
tients at the University of Minnesota undergoing a RIC HCT for
Oral Presentations S179AML in CR1 from 2001-2008. Sixty-one patients were available for
evaluation. Alongwith demographics we reviewed cytogenetics at di-
agnosis, number of induction chemotherapy cycles required to
achieve CR, pre-HCT consolidation therapy, and comorbidity score
at HCT. Impact of pre-HCT consolidation was analyzed in relation
to overall survival (OS), relapse, and transplant related mortality
(TRM).
Patients were a median of 56 years old (range 24-74) and received
either HLA matched sibling (n5 18), cord blood (n5 42) or unre-
lated donor (n5 1) grafts following cylophosphamide, fludarabine
and low dose total body irradiation along with CSA andmycopheno-
late for GVHD prophylaxis. Transplants were all during CR1 and
performed at a median of 5 (range 1.5–8.6) months from diagnosis.
Twenty-six patients received pre-transplant consolidation and 35
received none: 58% and 40% in each group respectively had high
risk cytogenetics.
Results:Of 61 patients, 43% (n5 26) received pre-HCT consolida-
tion therapy, 19 of whom (73%) received 1 cycle (range 1-3). Expo-
sure to pre-HCT consolidation therapy did not significantly alter 2
year OS or incidence of relapse and did not increase TRM. (Table)
In multivariate analysis only HCT-CI significantly impacted 2
year TRM. Relative risk (RR) of TRM at 2 years for patients
with HCT-CI .2 was 4.74 (95% CI, 0.99 – 22.60, p5 0.05).
Exposure to pre-HCT consolidation therapy was associated with
a trend towards improved 2 year TRM with a RR of 0.21 (95%
CI, 0.03 – 1.28), p5 0.09). In multivariate analysis of relapse risk
at 2 years, exposure to consolidation therapy had no effect on
relapse: RR was 1.5 (95% CI, 0.47 – 4.82, p5 0.50). No other
variables tested in multivariate analysis (high comorbidity score,
higher number of induction cycles to achieve CR, or high risk
cytogenetics) impacted relapse.
Conclusion: Consolidation therapy prior to RIC HCT does not
reduce relapse or augment TRM. RIC HCT is less successful in
patients with high HCT-CI due to excess TRM. For patients
with confirmed CR1, consolidation prior to RIC HCT is not
needed.
Two Year Outcomes: Univariate Analysis
No Pre-HCT Consolidation Pre-HCT Consolidationn5 35 n5 26 P-ValueOS 48% (30-64%, 95% CI) 35% (12-59%, 95% CI) 0.74
Relapse 29% (14-45%, 95% CI) 43% (23-62%, 95% CI) 0.23
TRM 27% (12-43%, 95% CI) 6% (0-19%, 95% CI) 0.05LYMPHOMA/MULTIPLE MYELOMA
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MULTI-TUMOR-ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR
THERAPY OF HEMATOLOGIC MALIGNANCIES
Gerdemann, U., Christin, A., Cruz, C.R., Vera, J.F., Heslop, H.E.,
Brenner, M.K., Bollard, C.M., Rooney, C.M., Leen, A.M. Baylor College
of Medicine, Texas Children’s Hospital and TheMethodist Hospital, Hous-
ton, TX
Tumor immunotherapy using in vitro expanded cytotoxic T lym-
phocytes (CTLs) can effectively treat virus-associated malignancies
such as EBV +ve Hodgkin’s Lymphoma. However, extension to
non virus-associated malignancies has been complicated by the
low frequency of circulating T-cells reactive against tumor-
expressed antigens, which are often anergized or tolerized. To
overcome T-cell anergy we activated T cells in the presence of a po-
tent cytokine cocktail including IL12 (Th1 polarizing), IL7 and
IL15 (pro-survival/-proliferative), and IL-6 (Treg inhibitory). We
optimized the generation of polyclonal, multiTA-reactive CTLs
by combining these cytokines with autologous dendritic cells nu-
cleofected with combinations of DNA tumor antigen (TA)-encod-
ing plasmids or pulsed with multiple TA pepmixes as APCs. The
use of whole antigen increases the range of suitable patient HLA
polymorphisms beyond those matched to single peptides, while tar-geting multiple antigens simultaneously reduces the risk of tumor
immune evasion.
Antigen combinations were chosen based on their tumor expres-
sion profile. To target lymphoma we grouped SSX2, Survivin, and
MAGEA4 and were consistently able to generate multiTAA CTL
directed against these three antigens (n5 6 healthy donors). The
lines were polyclonal comprising CD4+ (mean 57+/-7%) and
CD8+ (mean 40+/-16%) T cells, with reactivity against SSX2, Survi-
vin and MAGEA4 (median 345, 290 and 255 spot forming units
(SFU)/1106 CTL respectively in IFNg ELIspot, n5 6). The
CTLs were cytolytic against autologous SSX2 and Survivin pep-
mix-pulsed targets (mean 53% and 30% specific lysis, E:T 40:1)
and against whole Survivin antigen-expressing fibroblasts (30% spe-
cific lysis, E:T 100:1) with no recognition of non-transduced control
targets (9%) in a standard Cr51 release assay. For leukemia we
targeted WT1, Prame, PR3, and Survivin and generated CTL lines
with reactivity against WT1 (mean 733 SFU), PRAME (mean 555
SFU), PR3 (mean 145 SFU), and Survivin (mean 32 SFU/1106
CTL), n5 2.
Hence it is feasible to generate single tumor specific CTL lines
that target multiple tumor antigens simultaneously thereby reducing
the risk of tumor escape and simplifying clinical application.65
DENDRITIC CELL TUMOR FUSION VACCINATION IN CONJUNCTIONWITH
AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
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Autologous stem cell transplantation (ASCT) for multiple mye-
loma (MM) offers a unique setting to explore the role of immuno-
therapy in eradicating malignancy. Our group has developed
a cancer vaccine whereby dendritic cells (DCs) are fused with autol-
ogous tumor cells. We are conducting a clinical trial in which MM
patients undergo ASCT followed by vaccination with 3 doses of
DC/MM fusions (cohort 1). A second cohort receives an additional
vaccine prior to stem cell collection (cohort 2). To date, 26 patients
have been enrolled in cohort 1 and 9 in cohort 2. Adherent mononu-
clear cells were isolated from leukapheresis collections and cultured
with GM-CSF, IL-4 and TNFa to generate DCs. MM cells were
isolated from bone marrow and were identified by expression of
CD38 or CD138. DC and MM cells were co-cultured with PEG
and fusion cells were quantified by determining the percentage of
cells that co-express unique DC and MM antigens. Mean fusion
efficiency was 38%, mean dose generated was 3.6  106 fusion cells.
Fusion cells potently stimulated allogeneic T cell proliferation in
vitro (mean stimulation indexes were 13, 60, and 32 for T cells stim-
ulated by MM cells, DCs, and fusion cells respectively). Adverse
events were mild, and included injection site reactions, pruritis,
myalgias, fever, and tachycardia. ASCTwas associated with suppres-
sion of measures of cellular immunity. Circulating CD4 cells were
depressed post-transplant, and CD4:CD8 ratios remained inverted
for .10 months. Following transplant, T cell response to PHA
and tetanus toxoid were depressed. In contrast, an increase in circu-
lating tumor reactive lymphocytes was noted, as determined by T
cell expression of IFN following ex vivo coculture with autologous
myeloma cell lysate (Mean percentage of tumor reactive CD8 cells
was 1 and 7.7 pre and post-transplant, respectively; mean percentage
of CD4 cells was 0.9 and 3.2). A further amplification of tumor reac-
tive lymphocytes was seen with vaccination (mean percentage of
CD4 and CD8 tumor reactive T cells was 6.4 and 13.4, respectively).
24 patients have completed follow up. 3 patients achieved CR at
1 month following ASCT. An additional 7 patients obtained a CR
following completion of vaccinations, supporting a role for post-
transplant immunotherapy in mediating elimination of disease. In
summary, fusion cell vaccination in conjunction with ASCTwas well
tolerated, induced anti-tumor immunity and induction of post-trans-
plant complete response.
